Piatkowski TM, White KM, Hides LM, Obst PL. Australia’s Adonis: understanding what motivates young men’s lifestyle choices for enhancing their appearance. Australian Psychol. 2020;55(2):156–68.
Cohen J, Collins R, Darkes J, Gwartney D. A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States. J Int Soc Sports Nutr. 2007;4:12.
Bonnecaze AK, O’Connor T, Aloi JA. Characteristics and attitudes of men using anabolic androgenic steroids (AAS): a Survey of 2385 men. Am J Mens Health. 2020;14(6):1557988320966536.
Hope VD, Walker Bond V, Boardley I, Smith J, Campbell J, Bates G, et al. Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise. Drugs: Education, Prevention and Policy. 2023;30(5):461-73.
Mullen C, Whalley BJ, Schifano F, Baker JS. Anabolic androgenic steroid abuse in the United Kingdom: an update. Br J Pharmacol. 2020;177(10):2180–98.
Horwitz H, Andersen JT, Dalhoff KP. Health consequences of androgenic anabolic steroid use. J Intern Med. 2019;285(3):333–40.
Shankara-Narayana N, Yu C, Savkovic S, Desai R, Fennell C, Turner L, et al. Rate and extent of recovery from reproductive and cardiac dysfunction due to androgen abuse in men. J Clin Endocrinol Metab. 2020;105(6):dgz324.
Pope HG Jr., Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry. 1994;51(5):375–82.
Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergård A, et al. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open. 2013;3(9):e003207.
Kanayama G, Hudson JI, DeLuca J, Isaacs S, Baggish A, Weiner R, et al. Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem. Addiction. 2015;110(5):823–31.
Rasmussen JJ, Selmer C, Østergren PB, Pedersen KB, Schou M, Gustafsson F, et al. Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case-control study. PLoS One. 2016;11(8):e003207.
Smit DL, Buijs MM, de Hon O, den Heijer M, de Ronde W. Disruption and recovery of testicular function during and after androgen abuse: the HAARLEM study. Hum Reprod. 2021;36(4):880–90.
Pope HG Jr, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry. 1988;145(4):487–90.
Sharma A, Grant B, Islam H, Kapoor A, Pradeep A, Jayasena CN. Common symptoms associated with usage and cessation of anabolic androgenic steroids in men. Best Pract Res Clin Endocrinol Metab. 2022;36(5):101691.
Zitzmann M. Testosterone, mood, behaviour and quality of life. Andrology. 2020;8(6):1598–605.
Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy. 2012;32(10):910–9.
Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Jr. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966–78.
Karavolos S, Reynolds M, Panagiotopoulou N, McEleny K, Scally M, Quinton R. Male central hypogonadism secondary to exogenous androgens: a review of the drugs and protocols highlighted by the online community of users for prevention and/or mitigation of adverse effects. Clin Endocrinol (Oxf). 2015;82(5):624–32.
Smit DL, de Hon O, Venhuis BJ, den Heijer M, de Ronde W. Baseline characteristics of the HAARLEM study: 100 male amateur athletes using anabolic androgenic steroids. Scand J Med Sci Sports. 2020;30(3):531–9.
Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 2006;38(4):644–51.
de Ronde W, Smit DL. Anabolic androgenic steroid abuse in young males. Endocr Connect. 2020;9(4):R102–r111.
Rochoy M, Danel A, Chazard E, Gautier S, Berkhout C. Doping with aromatase inhibitors and oestrogen receptor modulators in steroid users: analysis of a forum to identify dosages, durations and adverse drug reactions. Therapie. 2022;77(6):683–91.
Kimergård A, McVeigh J. Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study. Harm Reduct J. 2014;11:19.
Statistics ON. Census 2021. 2023.
Amaral JMX, Kimergard A, Deluca P. Prevalence of anabolic steroid users seeking support from physicians: a systematic review and meta-analysis. BMJ Open. 2022;12(7):e056445.
Pope HG, Kanayama G, Ionescu-Pioggia M, Hudson JI. Anabolic steroid users’ attitudes towards physicians. Addiction. 2004;99(9):1189–94.
Rowe R, Berger I, Copeland J. No pain, no gainz? Performance and image-enhancing drugs, health effects and information seeking. Drugs: Educ Prev Policy. 2017;24(5):400–8.
Magnolini R, Falcato L, Cremonesi A, Schori D, Bruggmann P. Fake anabolic androgenic steroids on the black market – a systematic review and meta-analysis on qualitative and quantitative analytical results found within the literature. BMC Public Health. 2022;22(1):1371.
Al Hashimi M. The deleterious effects of anabolic androgenic steroid abuse on sexual and reproductive health and comparison of recovery between treated and untreated patients: single-center prospective randomized study. Andrologia. 2022;54(11):e14576.
Armstrong JM, Avant RA, Charchenko CM, Westerman ME, Ziegelmann MJ, Miest TS, et al. Impact of anabolic androgenic steroids on sexual function. Transl Androl Urol. 2018;7(3):483–9.
Griffiths S, Henshaw R, McKay FH, Dunn M. Post-cycle therapy for performance and image enhancing drug users: a qualitative investigation. Perform Enhancement Health. 2017;5(3):103–7.
Dunn M, Piatkowski T. Investigating the impact of COVID-19 on performance and image enhancing drug use. Harm Reduct J. 2021;18(1):124.
Piatkowski T, Puljevic C, Francis C, Ferris J, Dunn M. They sent it away for testing and it was all bunk: exploring perspectives on drug checking among steroid consumers in Queensland, Australia. Int J Drug Policy. 2023;119:104139.
Grant B, Pradeep A, Minhas S, Dhillo WS, Quinton R, Jayasena CN. Survey of endocrinologists managing recovery from anabolic androgenic steroid induced hypogonadism. Reprod Fertil. 2023;4(1):e220097.
Jayasena CN, Anderson RA, Llahana S, Barth JH, MacKenzie F, Wilkes S, et al. Society for endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol (Oxf). 2022;96(2):200–19.
Wenker EP, Dupree JM, Langille GM, Kovac J, Ramasamy R, Lamb D, et al. The use of HCG-Based combination therapy for recovery of spermatogenesis after testosterone use. J Sex Med. 2015;12(6):1334–7.
Huijben M, Lock M, de Kemp VF, de Kort LMO, van Breda HMK. Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis. Andrology. 2022;10(3):451–69.
Add Comment